Medicolegal Risks in Hair Transplantation: Key Lessons from North America

Why these skin and hair studies matter

If you worry about your skin, hair, or a treatment you’re considering, recent research offers useful, real-world takeaways. This roundup looks at five recent studies on topics people often ask about: legal problems after hair transplants, how neighborhood poverty relates to skin cancer thickness, early flares in atopic dermatitis treatment trials, how well the drug adalimumab holds up for hidradenitis suppurativa, and whether adding topical vitamin C to yellow light helps melasma.

Hair transplants and legal complaints: what patients and clinics should know

Researchers reviewed North American court cases and Canadian regulatory complaints about hair transplantation to see what problems came up most often. They found 35 legal cases from 1980 through 2026 and 6 regulatory complaints in Canada. The two most common issues were claims of medical malpractice and complaints about inadequate informed consent. Scarring was the physical complication reported most often. (Source: Journal of Cosmetic Dermatology, Medicolegal Issues in Hair Transplantation).

Many disputes came down to unmet cosmetic expectations. Patients said results didn’t match what they were told, or that they weren’t properly warned about risks, alternatives, likely outcomes, and the limits of what a transplant could do. Complaints also involved who actually performed parts of the procedure. Some cases said doctors delegated too much to nurses or technicians or failed to supervise them properly.

What this means for people considering a transplant: ask clear, detailed questions about the plan. Find out who will perform each step, what the likely cosmetic outcome is, how many grafts or session(s) may be needed, and what scarring could look like. Clinics should document these conversations carefully.

For clinicians, the review underscores practical steps to reduce problems: clearly define team roles, ensure appropriate physician oversight, document informed consent and counseling, and set realistic expectations about hairline design, graft density, coverage, and the possibility of further procedures. (Source: Journal of Cosmetic Dermatology, Medicolegal Issues in Hair Transplantation).

Neighborhood disadvantage and thicker head-and-neck melanomas

A study of 321 people with primary head and neck cutaneous melanoma found that socioeconomic disadvantage in a patient’s neighborhood was linked with thicker tumors at surgery. Tumor thickness is measured as Breslow thickness, which is a key way doctors estimate how deep a melanoma has grown into the skin.

After accounting for age and other factors, patients from the most deprived neighborhoods had tumors that were on average 1.40 mm thicker than those from the least deprived neighborhoods. They also had a longer time from biopsy to surgery — about a 33% longer interval, which here was roughly a 10-day difference. Finally, there was a larger difference between the initial biopsy thickness and the final surgical Breslow thickness for people living in more deprived areas. These differences remained even after the researchers adjusted for surgical delay. (Source: The Laryngoscope, Association of Neighborhood Deprivation With Breslow Thickness in Head and Neck Cutaneous Melanoma).

Why this matters: social and access factors can affect how advanced a melanoma is at treatment, not just whether it’s found in the first place. Timely referrals, careful biopsy and sampling, and attention to barriers to specialty care can all help.

Early “flares” on new atopic dermatitis treatments: is it the drug or the skin’s natural ups and downs?

Investigators reviewed early dermatitis-related events reported in phase 3 trials of systemic (whole-body) treatments for moderate-to-severe atopic dermatitis, a chronic eczema condition. They looked at trials of several drugs, including dupilumab, lebrikizumab, tralokinumab, nemolizumab, upadacitinib, and abrocitinib.

Reports of treatment-emergent events labeled “atopic dermatitis,” “dermatitis,” or “eczema” varied a lot. In treatment groups the rates ranged from about 1% to 29%, and in some placebo groups they were as high as 41%. Differences in how severe patients were at the start, what topical creams people continued using, rescue-treatment rules, and how “worsening” was defined made direct comparisons between drugs hard to interpret. (Source: Journal of the European Academy of Dermatology and Venereology, When Treatment Meets Natural History: Understanding Early Dermatitis-Related Adverse Events in Systemic Atopic Dermatitis Trials).

The authors suggest that many early “worsenings” may reflect natural ups and downs of atopic dermatitis, an incomplete response, or differences in reporting, rather than being caused directly by the drugs. They recommend counseling patients that temporary worsening can occur when starting a new systemic therapy. Sticking with prescribed skin creams and moisturizers during the first weeks is important, and switching a working systemic treatment too quickly may not be needed unless the worsening is persistent or clearly significant.

The review also calls for standardized definitions of flares in future trials so clinicians and patients can better understand what to expect.

Adalimumab for hidradenitis suppurativa: who keeps benefiting?

A multicenter study followed 135 adults who started adalimumab as their first biologic for hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition that causes painful bumps and tunnels in areas such as the underarms and groin.

Patients were grouped by how they responded over time: primary failure (no meaningful response by 12–24 weeks), secondary failure (lost response between 24 weeks and 2 years), or sustained response (benefit beyond 2 years). Overall, 26% had primary failure, 39% had secondary failure, and 36% had a sustained response. (Source: Journal of Dermatological Treatment, Predictors of Adalimumab Durability in Hidradenitis Suppurativa: A Multicenter Cohort Study).

On adjusted analysis, the only independent predictor of lower adalimumab durability was having Hurley stage 3 disease. Hurley staging is a way to grade HS severity; stage 3 means more widespread disease with scarring and tunnels. Other factors such as higher body mass index, diabetes, and lower hemoglobin were linked to shorter durability in simple (unadjusted) analyses but were not significant after accounting for multiple variables. Routine lab tests like white blood cells or albumin did not predict who would stay on the drug.

What to take away: people with advanced, structurally changed HS (Hurley stage 3) may be less likely to have long-lasting benefit from adalimumab alone. For those patients, a combination of medical and procedural treatments may be needed, and treatment plans should be individualized in discussion with a clinician.

Melasma: does adding 20% vitamin C to yellow light therapy help?

A randomized, double-blind, placebo-controlled trial at a single center tested whether combining topical 20% vitamin C with yellow light therapy gives better results for melasma than yellow light alone. Melasma is a common form of hyperpigmentation, often on the face.

The study found that the combination produced greater improvement in pigmentation and overall melasma severity than yellow light by itself. Side effects were generally mild and manageable for both groups. (Source: Journal of Cosmetic Dermatology, Efficacy and Safety of Yellow Light Monotherapy Versus Yellow Light Combined With 20% Vitamin C for the Treatment of Melasma).

Because this was a single-center study with a limited number of participants, the authors say larger and longer trials are needed before the combination can be widely recommended.

Keeping an eye on visible changes

For visible skin issues — new or changing moles, dark spots that grow or bleed, wounds that don’t heal, or worsening rashes — keeping a simple photo diary can help you and your doctor track changes over time. Clear, dated photos taken under similar lighting and from the same distance are most useful when you bring them to an appointment.

When to see a doctor

See a clinician promptly if you notice a changing, growing, bleeding, or painful mole or lesion. For suspected infections after a procedure, worsening pain, redness spreading, fever, or signs of poor healing, seek medical attention. If a chronic skin condition gets much worse after starting a new treatment, check in with your prescribing clinician before stopping or switching therapies.

For cosmetic procedures like hair transplants, ask questions up front. If expectations aren’t being met, voice concerns early so plans can be adjusted or documented.

Short disclaimer

This article summarizes recent research for general information and does not provide medical advice. Treatment choices should be discussed with your dermatologist or health care provider. If you have serious or rapidly changing symptoms, seek professional care promptly.

Sources

1. Gupta AK, Teasell E, Talukder M. Medicolegal Issues in Hair Transplantation: A Review of North American Court Decisions and Canadian Regulatory Complaints. Journal of Cosmetic Dermatology. 2026. (Source: Journal of Cosmetic Dermatology, Medicolegal Issues in Hair Transplantation).
2. Thomas EA, Davis MJ, Stucken CL, et al. Association of Neighborhood Deprivation With Breslow Thickness in Head and Neck Cutaneous Melanoma. The Laryngoscope. Published online August 22, 2026. doi:10.1002/lary.70851. (Source: The Laryngoscope, Association of Neighborhood Deprivation With Breslow Thickness in Head and Neck Cutaneous Melanoma).
3. Dasilva DR, Soto-Gonzalez A, Alkiswani H, et al. When Treatment Meets Natural History: Understanding Early Dermatitis-Related Adverse Events in Systemic Atopic Dermatitis Trials. Journal of the European Academy of Dermatology and Venereology (Clinical Practice). 2026. doi:10.1002/jvc2.70423. (Source: Journal of the European Academy of Dermatology and Venereology, When Treatment Meets Natural History).
4. Young AT, Pannu A, Velaoras A, et al. Predictors of Adalimumab Durability in Hidradenitis Suppurativa: A Multicenter Cohort Study. Journal of Dermatological Treatment. 2026. doi:10.1080/09546634.2026.2719076. (Source: Journal of Dermatological Treatment, Predictors of Adalimumab Durability in Hidradenitis Suppurativa).
5. Du D, Liu X, Huang Y, Wu S, Jiang X. Efficacy and Safety of Yellow Light Monotherapy Versus Yellow Light Combined With 20% Vitamin C for the Treatment of Melasma: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Study. Journal of Cosmetic Dermatology. 2026. (Source: Journal of Cosmetic Dermatology, Efficacy and Safety of Yellow Light Monotherapy Versus Yellow Light Combined With 20% Vitamin C for the Treatment of Melasma).